Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome

Blood Transfusion

Volumn 8, Issue 3, 2010, Pages 203-210

  Caramazza, Domenica ^a   Quintini, Gerlando ^a   Abbene, Ignazio ^a   Lo Coco, Lucio ^a   Malato, Alessandra ^a   Di Trapani, Rosa ^a   Saccullo, Giorgia ^a   Pizzo, Giuseppina ^a   Palazzolo, Roberto ^a   Barone, Rita ^a   Mazzola, Giuseppina ^a   Rizzo, Sergio ^a   Ragonese, Paolo ^a   Aridon, Paolo ^a   Abbadessa, Vincenzo ^a   Siragusa, Sergio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; DRUG INDICATION; DRUG INFUSION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; RELAPSE; TREATMENT RESPONSE;

ADAM PROTEINS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77954397953     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2009.0101-09     Document Type: Article

References (56)

1. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-59.
2. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpurahemolytic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8.
3. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-7.
4. Rock G, Shumak K, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992; 32: 710-4.
5. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpurahemolytic uremic syndrome. N Engl J Med 1991; 325: 398-403.
6. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992; 80: 1890-5.
7. Hayward CPM, Sutton DMC, Carter WH Jr, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994; 154: 982-7.
8. Elkins SL, Wilson PP, Files JC, Morrison FS. Thrombotic thrombocytopenic purpura: evolution across 15 years. J Clin Apheresis 1996; 11: 173-5.
9. Lara PN Jr, Coe TL, Zhou H, et al. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 1999; 107: 573-9.
10. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96: 1223-9.
11. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Int Med 1999; 131: 453-62. (Pubitemid 29444437)
12. Fankouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13 deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-7.
13. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3.
14. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
15. Tsai H-M. Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 2002; 100: 3839-40.
16. Mannucci PM. Thrombotic thrombocytopenic purpura: a simpler diagnosis at last? Thromb Haemost 1999; 82: 1380-1.
17. Cines DB, Konkle BA, Furlan M. Thrombotic thrombocytopenic purpura: a paradigm shift? Thromb Haemost 2000; 84: 528-35.
18. Lankford KV, Hillyer CD. Thrombotic thrombocytopenic purpura: new insights in disease pathogenesis and therapy. Transfus Med Rev 2000; 14: 244-57.
19. Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-80.
20. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the haemolytic uremic syndrome. N Engl J Med 1998; 339: 1578-84.
21. Tsai H-M, Lian ECY. Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
22. Moore JC, Hayward CPM, Warkentin TE, Kelton. JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-6.
23. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72.
24. Raife TJ, Lentz SR, Atkinson BS, et al. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002; 99: 437-42.
25. Rick ME, Moll S, Taylor MA, et al. Clinical use of a rapid collagen-binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2002; 88: 598-604.
26. Rizvi MA, Vesely SK, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2000; 40: 896-901.
27. McMinn JR, Thomas IA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: an additional study of 78 consecutive patients. Transfusion 2003; 43: 415-6.
28. Allford SL, Hunt BJ, Rose P, Machin S. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemia. Br J Haematol 2003; 120: 556-73.
29. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology 2004. Washington DC: American Society of Hematology; 2004. p. 407-23.
30. Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005; 130: 768-76. (Pubitemid 43906650)
31. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
32. Quintini G, Barbera V, Iannitto E, Mariani G. Potential strategies for the treatment of plasma exchange-resistant thrombotic thrombocytopenic purpura. Br J Haematol 2001; 113: 560-2.
33. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol Rev 2008; 141: 149-69. (Pubitemid 351406218)
34. Kameda T, Dobashi H, Kittaka K, et al. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol 2007 ; 26: 2159-62.
35. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005 ; 84: 232-5. (Pubitemid 40425069)
36. Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-95.
37. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002; 71: 105-8.
38. Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2004; 2: 834-6.
39. Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77: 171-6.
40. Koulova L, Alexandrescu D, Dutcher JP, et al. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 2005; 78: 49-54. (Pubitemid 40023747)
41. Millward PM, Bandarenko N, Chang PP, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenic purpura with rituximab. Transfusion 2005; 45: 1481-6.
42. Scott SM, Szczepieorkowski ZM. Rituximab for TTP. Am J Hematol 2005; 80: 878.
43. Yassa SK, Blessios G, Marinides G, Venuto RC. Anti- CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 2005; 19: 423-6.
44. Daraibi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006; 125: 592-7.
45. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2006; 136: 451-61.
46. Rüfer A, Brodmann D, Gregor M, et al. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly 2007; 137: 518-24.
47. Chow KV, Carroll R, Branley P, et al. Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Intern Med J 2007; 37: 329-32. (Pubitemid 46744093)
48. Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008; 23: 151-6.
49. Arici B, Trendelenburg M. Successful treatment of thrombotic thrombocytopenic purpura (TTP) with rituximab. Ther Umsch 2008; 65: 710-2.
50. Lalmuanpuii J, Yalamanchili K, Fircanis S, Nelson JC. Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura. J Clin Apher 2009; 24: 18-20.
51. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti- ADAMTS13 autoantibodies. Thromb Haemost 2009; 101: 233-8.
52. Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995; 70: 319-23.
53. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Committee for Standards in Haematology, Blood Transfusion Task Force. Br J Haematol 2004; 126: 11-28.
54. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-8.
55. Mannucci PM, Lavoretano S, Peyvandi F. The thrombotic microangiopathies. Blood Transfus 2005; 3: 120-35.
56. Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96: 119-25.